Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. - Wikidata - awgldk - TriplyDB

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

http://www.wikidata.org/entity/Q34642136

about

Aflibercept Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Current targeted therapies in the treatment of advanced colorectal cancer: a review Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Pharmacologic resistance in colorectal cancer: a review Novel therapeutic agents in the treatment of metastatic colorectal cancer Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer Profile of nintedanib in the treatment of solid tumors: the evidence to date Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update Biomarkers of Angiogenesis in Colorectal Cancer Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Anti-angiogenic agents in metastatic colorectal cancer Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Molecularly targeted drugs for metastatic colorectal cancer Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer Anti-angiogenesis in prostate cancer: knocked down but not out Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Cancer concepts and principles: primer for the interventional oncologist-part II The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer Treatment of metastatic colorectal cancer: focus on panitumumab Management of locally advanced and metastatic colon cancer in elderly patients Regorafenib in metastatic colorectal cancer.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Role of targeted therapy in metastatic colorectal cancer Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients From bench to bedside: lessons learned in translating preclinical studies in cancer drug development

P2860

Q24600199-A306CA1B-0835-4B19-9127-A32DC9C2D33C Q26738801-12605FB8-8027-41E1-88EF-A45456C6F753 Q26740067-17A6A955-56B6-4883-AD08-CCA686661BCE Q26740812-694916F4-1FA6-4575-A41F-F2F46AA59C08 Q26745418-5119AAA6-A8B3-4191-8DF6-09E544FE5C3C Q26748924-E7A356DF-7577-438A-AF15-DDA663B3459B Q26749012-101A14D6-2E7A-48D1-A156-EAA616E3605C Q26751344-A1858981-6D10-4B7F-BA9C-F72826EFA177 Q26752747-87835A4D-D1C0-4FD1-910A-BCF55E9F9E07 Q26764892-245650D0-CA71-4A35-B2ED-8FD3DEDCF9C5 Q26769850-3F5689A1-442A-451F-80AD-67AB717FDE23 Q26769932-B7D31822-08F3-4BAD-BE6C-EDBBAD005A6C Q26769935-669F5679-E7F3-4DD3-BA66-84361BE9D4D7 Q26775134-1704CA62-5DCB-48AF-9EC5-3C98BECEF27A Q26775522-CE3DB064-4779-43AF-822C-9A60CFAAEF64 Q26778004-DC85EC03-CD66-4000-92E1-65022D65EF27 Q26778891-32D79AC7-25FA-4E6B-80F8-860D23602B3C Q26786243-52E71CE3-D007-4C5E-A4BD-83372A5A3071 Q26799458-8A68E637-540B-4FF3-A692-D2265DF6D830 Q26801911-D1CFD641-5700-47AC-8913-EF42B6D0C1E0 Q26826817-1879E095-A940-4A05-88C1-CC2EF3A0EB00 Q26828735-8AEBD9BC-A424-436B-AACF-11B91301885A Q26830219-E02D2CF3-9E6A-40F4-9BDD-8675CC0BDE95 Q26851183-F7514DF5-2623-4EB0-A008-FF03228FEC5C Q26853604-A7BF2B3A-5F6B-4F0D-9CB9-8FFD61CF07F0 Q26858892-B1CCBC56-7803-4CB0-A2BD-CAE87B47E42D Q27002388-2B18455B-9598-48EB-B116-86A4C9DFC614 Q27002538-13FEC4F4-8EE8-4FC6-A4FE-EC786B385C88 Q27010961-702C276E-5DD9-4810-9D4A-4D78410A95AB Q27011366-29E7A41C-91E6-4A12-8872-99A6232B9BF0 Q27022954-EFB81DB8-93B7-4A54-BAE4-BF7CC555EA74 Q27026129-518CED20-5B02-43A2-8457-3A6B3848C352 Q27852864-D216DF48-6567-42E3-888C-A7885FE70E6D Q28066460-ACA0C222-7A8B-4EC6-AD6F-10F33056435B Q28067753-2AEA89D9-0726-4BEA-952A-1466181C4AE3 Q28068654-1BF78A1B-B9DF-4CF2-8624-8AEF0555F4D0 Q28068817-D0C55192-A8C6-4B93-864F-2D962B461055 Q28071933-01B58606-CCA9-4441-9051-3B7046C7B2A0 Q28079328-97AF78BD-07A1-419F-9D25-01B9F7F5891D Q28533949-5B60BF14-3FC1-4260-B42A-3821A039F39C

P2860

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

http://www.wikidata.org/entity/Q34642136

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@ast

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@en

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@nl

type

label

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@ast

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@en

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@nl

prefLabel

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@ast

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@en

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@nl

P1433

Q34642136-E7879224-5DCE-4872-8A78-2695C01F3FAD

P1476

Q34642136-25960FED-4DC0-4DA0-878C-0A844D8FDFC6

P2093

Q34642136-03D39924-1F54-4DC7-935B-CA29CFB47128

Q34642136-0F4689CF-A9C8-426F-8A6B-12B586D55B1D

Q34642136-2B1F2B70-9782-41E0-9FAA-D28FE51521DB

Q34642136-352DB1EA-487D-4F5E-AE31-926B6220831B

Q34642136-45EB83A2-4AB1-4883-8E55-1FFA8504BC65

Q34642136-68BCAE17-B41A-4011-9698-E9BFFCCDD17B

Q34642136-8F7135EC-141D-4654-9BC5-C0F3F0A47BB0

Q34642136-A8C3D667-27B4-4470-B101-17420AA4562D

Q34642136-B272B6BF-64E0-47DB-9A62-9DA56C4BB10F

Q34642136-C76126B0-31B9-408F-88E3-0A8C459DAD14

P304

Q34642136-3B343387-A0AA-4241-AC6A-8C2EF9C97338

P31

Q34642136-3CB7FFFA-8B59-41EE-94BB-7EA51107C3BE

P356

Q34642136-3D86DA71-7E79-400B-8499-16D52AB194AD

P407

Q34642136-E01F4261-ADB9-4F66-9AB6-32CA44DC96E8

P433

Q34642136-25350E89-3746-43D2-8F2B-61ED4666598B

P478

Q34642136-992DD881-755A-467B-8676-FE81C405C5E8

P50

Q34642136-6B61547B-3A05-4F1B-A06B-C7DB8EB142CE

Q34642136-F4B29051-A641-42FB-8A81-FCA166A769AD

P577

Q34642136-5CFD0C72-ECF0-4B1A-BB41-60852FB9A9C0

P698

Q34642136-3C6F502B-FDA1-4E40-BE3B-3698AD253437

P921

Q34642136-A7A1D680-2381-4644-BFED-36750DEB5781

Q34642136-C5B1C396-18CA-4681-8E75-1214C578877A

Q34642136-DE0C84FF-EC12-4B05-9146-61CC14A9CE5B

P356

JCO.2012.42.8201

P1433

Journal of Clinical Oncology

P1476

Addition of aflibercept to flu ...... an oxaliplatin-based regimen.

@en

P2093

Alexia Tellier

http://www.w3.org/2001/XMLSchema#string

Carmen Allegra

http://www.w3.org/2001/XMLSchema#string

David Ferry

http://www.w3.org/2001/XMLSchema#string

Guy A van Hazel

http://www.w3.org/2001/XMLSchema#string

Hans Prenen

http://www.w3.org/2001/XMLSchema#string

Jana Prausová

http://www.w3.org/2001/XMLSchema#string

Joe McKendrick

http://www.w3.org/2001/XMLSchema#string

Jonathan Polikoff

http://www.w3.org/2001/XMLSchema#string

Paul Ruff

http://www.w3.org/2001/XMLSchema#string

Radek Lakomy

http://www.w3.org/2001/XMLSchema#string

P304

3499-3506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.42.8201

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Eric Van Cutsem

Josep Tabernero

P577

2012-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22949147

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase III clinical trial